ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,969.34
0.35%
Dow Jones
44,296.51
0.97%
US Dollar vs MXN
20.4285
0.00%
Brent Oil
74.65
0.00%
Bitcoin
98,870.04
-0.16%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Verastem Inc (VSTM)

  7. Verastem Inc (VSTM) Noticias

Verastem Inc

Verastem Inc (VSTM)

NASDAQ
4.00
0.07
(1.78%)
Cerrado 23 Noviembre 3:00PM
Delayed by 15 minutes
4.09
0.09
(2.25%)
Fuera de horario: 6:59PM
Delayed by 15 minutes

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Premium

VSTM Noticias

Solo noticias oficiales

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Edgar (US Regulatory)
14 Noviembre 2024
VSTM (1.78%)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Edgar (US Regulatory)
12 Noviembre 2024
VSTM (1.78%)

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Edgar (US Regulatory)
08 Noviembre 2024
VSTM (1.78%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
07 Noviembre 2024
VSTM (1.78%)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Edgar (US Regulatory)
06 Noviembre 2024
VSTM (1.78%)

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Edgar (US Regulatory)
24 Octubre 2024
VSTM (1.78%)

Form 8-K - Current report
Edgar (US Regulatory)
17 Octubre 2024
VSTM (1.78%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
09 Octubre 2024
VSTM (1.78%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
24 Septiembre 2024
VSTM (1.78%)

VSTM Discussion

Ver más
axelvento axelvento 1 mes hace
stay tuned-----The oral presentation will include updated safety and efficacy data from the RAMP 201 trial evaluating the combination of avutometinib, an oral RAF/MEK clamp, and defactinib, an oral, selective FAK inhibitor, in patients with recurrent low-grade serous ovarian cancer (LGSOC), including overall response rate, progression free survival, and duration of response.

Company to host investor conference call and webcast on October 17, 2024, at 4:30 pm EDT
👍️0
Monksdream Monksdream 3 meses hace
VSTM under $3
👍️0
Monksdream Monksdream 4 meses hace
VSTM new 52 week low
👍️0
Termite7 Termite7 6 meses hace
https://www.verastem.com/research/pipeline/ Good pipeline!!!
👍️0
TheFinalCD TheFinalCD 6 meses hace
For those who are curious why $VSTM is down 60% on premarket, being 50% yesterday afterhours, despite positive RAMP 205 data (High ORR)

https://x.com/WallStDayTrader/status/1793988987092369420
https://x.com/Dogtor01416800/status/1793983764386939192
👍️ 1
TheFinalCD TheFinalCD 6 meses hace
4.75 NOW VSTM over $18
👍️0
pmach64 pmach64 6 meses hace
Brutal morning sell off after what appeared to be good news.
👍️0
tw0122 tw0122 6 meses hace
VSTM over $18
👍️0
Monksdream Monksdream 7 meses hace
VSTM over $10
👍️0
Harbor6460 Harbor6460 1 año hace
Read about it at 3.00 it looks like.
👍️0
muchogusto muchogusto 1 año hace
Worth reading
https://www.onclive.com/view/avutometinib-defactinib-combo-generates-early-efficacy-signals-in-low-grade-serous-ovarian-cancer
👍️0
Harbor6460 Harbor6460 1 año hace
It’s death after a RS. Wait for 4.00 or way under. Then Good risk reward
👍️0
muchogusto muchogusto 1 año hace
So, what is next for VSTM in terms of catalysts and results? Any upcoming data points? Is it now free from funding worries and free to focus on producing results? Tartia, your input would be appreciated.
👍️0
Harbor6460 Harbor6460 1 año hace
Happy I hit and run. I would consider this at under 4.00
👍️0
Harbor6460 Harbor6460 1 año hace
They definite are diluting. They need money. But in long run great for shareholder
👍️0
The Night Stalker The Night Stalker 1 año hace
highest volume in history -insert dd-
👍️0
Harbor6460 Harbor6460 1 año hace
Yep
👍️0
knrorrel knrorrel 1 año hace
nice
👍️0
The Night Stalker The Night Stalker 1 año hace
oh my
👍️0
Triple nickle Triple nickle 1 año hace
Looks like dilution
👍️0
KeepOn KeepOn 1 año hace
Looks like real support at a dollar. Could be ready for next leg.
👍️0
Triple nickle Triple nickle 1 año hace
Added the dip
👍️0
Triple nickle Triple nickle 1 año hace
I post so others can ride with me to the victory circle so to speak.
I really like it when peeps get a good run.
👍️0
Invest-in-America Invest-in-America 1 año hace
VSTM: Well, Capt. T-N, you certainly scored MONSTER TIME on this one today, Dude!!! (EASY money for you, or WHAT, Bro!!! CONGRATS!!!)
👍️0
Harbor6460 Harbor6460 1 año hace
Halted?
👍️0
jchords jchords 1 año hace
Nice call
👍️0
Triple nickle Triple nickle 1 año hace
Okay nice run folks
👍️0
Triple nickle Triple nickle 1 año hace
.75 comin up

1.00 soon
👍️0
Triple nickle Triple nickle 1 año hace
LV2 still looks real thin
.75 ?
👍️0
Triple nickle Triple nickle 1 año hace
Really Good Friday here
👍️0
power11 power11 1 año hace
WHAT NEWS ??????
👍️0
Triple nickle Triple nickle 1 año hace
I’d be nice waking up to thirty bucks a share from this level
👍️0
shurtha2000 shurtha2000 1 año hace
This kind of news you can skip PHASEIII and go straight to approval
👍️0
Tartiaboy Tartiaboy 1 año hace
Next week it should run strong.
👍️0
Harbor6460 Harbor6460 1 año hace
This news is very positive
👍️0
Triple nickle Triple nickle 1 año hace
Peeps see double tops and think sell
Just bust through it
👍️0
Tartiaboy Tartiaboy 1 año hace
You would think.
👍️0
Triple nickle Triple nickle 1 año hace
Break past .52 come on
👍️0
Harbor6460 Harbor6460 2 años hace
Insiders are buying options. Time to load imo. Could see 2.00-3.00 like nothing
👍️0
SaltyOne SaltyOne 2 años hace
I'm with you on this one and so are the Baker Bros
👍️0
Harbor6460 Harbor6460 2 años hace
Never seen a board that nobody post wtf. Lol. We got things coming imo
👍️0
Harbor6460 Harbor6460 2 años hace
2 million volume yesterday. That’s a fund imo. I told you this was coming. Price of a stock does not reflect market value. This combo of drugs is a monster. I see 5-15.00 by Jan 2025
👍️0
Tartiaboy Tartiaboy 2 años hace
In addition to the progress with avutometinib + defactinib in LGSOC ONCT is moving two KRAS-G12C projects forward: avutometinib + sotorasib and avutometinib + adagrasib in KRAS-(G12C) NSCLC. Preclinical data suggests that we should see synergy with these combinations. I believe that the avuto + soto initial readout should happen at any time and this will be a big deal if the data is encouraging. In the preclinical data VSTM demonstrated that the synergistic effect of avutometinib + a G12C inhibitor was further enhanced with the addition of defactinib. I hope that they advance this G12C program with both the doublet and the triplet approach.

Clinical progress with the LGSOC program and the KRAS-G12C programs justify a much higher market cap than we have now. Any success with pancreatic cancer would be a total game-changer. The LGSOC and KRAS-G12C programs and low market cap provide a low risk opportunity to be in on the big prize which is Pancreatic cancer.
👍️0
Tartiaboy Tartiaboy 2 años hace
The RAMP201 and FRAME data for LGSOC is excellent so far. We should have final data readout in about 18 months (IMO). This data is expected to support an AA filing with the FDA for LGSOC. The current PPS does not reflect the significance of this. In addition, we have near term pending data on RAMP203 for RAS(G12C) NSCLC. Positive results with RAMP203 will further enhance value and help establish Avutometinib as a valid approach to RAS pathway cancers.

As an aside, I have my eyes on Akena's RAF:MEK clamp which may be even better than Avutometinib. The only problem is that Akena's molecule is several years behind Avuto in development.
👍️0
Tartiaboy Tartiaboy 2 años hace
I think that anyone interested needs to follow-up reading this PR by listening to the webcast presentation. It provides a more granular and encouraging overview than the PR alone does. I felt much more encouraged after hearing the overview and seeing the slides.

For instance the 28% ORR is interim data, not fully matured data. If one includes the 3 unconfirmed PRs the ORR is 38%. That's very good. If approved there will be TWO drugs approved.
👍️0
DrHarleyboy DrHarleyboy 2 años hace
Regulatory Update Following Type B FDA Meeting on LGSOC Program

A recent FDA meeting was held to discuss the encouraging results to date of the ongoing RAMP 201 trial evaluating avutometinib ± defactinib among patients with recurrent LGSOC, confirm the go forward treatment regimen selection and discuss the regulatory path forward. The combination of avutometinib with defactinib has been selected vs monotherapy as the go forward treatment in all recurrent LGSOC regardless of KRAS status, acknowledging the demonstrated contribution of defactinib.

The Company intends to include mature data from RAMP 201, the Verastem sponsored clinical trial, and the FRAME study, led by The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust to potentially support filing for accelerated approval. Both studies are evaluating avutometinib and defactinib in patients with recurrent LGSOC. The Company is in ongoing discussions with the FDA on the confirmatory study and plans to provide an update after agreement with the FDA. Continued enrollment in the combination arm of RAMP 201 is planned to expand the clinical experience in anticipation of initiation of a confirmatory study.

“We appreciate the productive and ongoing discussions with the FDA regarding the progress of our LGSOC program, including the alignment around key next steps as part of our breakthrough therapy designation,” said Brian Stuglik, CEO of Verastem Oncology. “With the encouraging results of the RAMP 201 Part A interim analysis and the FRAME study, we will work expeditiously to prepare to file for an accelerated approval that encompasses the totality of the data from both trials as well as progress on the confirmatory study.”

https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-announces-positive-data-and-regulatory-update
👍️0
Tartiaboy Tartiaboy 2 años hace
I already one a nice chunk. Listened to the webcast. Data looks very impressive. Open to discussing it.
👍️0
DrHarleyboy DrHarleyboy 2 años hace
Ramp 201 Data Updated, and a Private Placement secured.

BUY
👍️0
Harbor6460 Harbor6460 2 años hace
Looks like Big mews coming in next 3-6 months
👍️0
DrHarleyboy DrHarleyboy 2 años hace
Well, not time like the present to start a position, I doubt it can get much worse except go to $0.....

Still waiting on some results that will make or break this tiny Biotech.
👍️0

Su Consulta Reciente

NASDAQ
VSTM
Verastem
NYSE
GIC
Global Industrial
BIT
1ACS
ACS Actividades de Const...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados